| | About Onychomycosis A common and increasingly recognized medical condition, onychomycosis is a chronic and recurring fungal infection of the toenails or the fingernails resulting in thick, flaky or discolored nails. Without treatment, the condition will not go away and may become worse, resulting in pressure, irritation, serious pain and disability. According toPodiatry Today, it has been estimated that approximately 35 million patients in the United States suffer from onychomycosis. Of this group, approximately 18 percent, or 6.3 million patients, have been diagnosed with the disease after seeking treatment by podiatrists, dermatologists and other physicians. About Pramiconazole (previously known as Azoline) Pramiconazole, a novel antifungal agent, is being developed by Barrier Therapeutics as a potential once weekly treatment for chronic fungal infections such as onychomycosis (nail fungus), as well as a potential short course treatment for acute skin and mucosal fungal infections.In vitro pramiconazole has been shown to possess broad spectrum potency against dermatophytes, yeasts and molds. In October 2007, the Company reported positive interim data from its Phase 2a trial with once weekly dosing of pramiconazole in the treatment of toe nail onychomycosis. In March 2007, the Company reported positive results from a Phase 2b dose ranging study with pramiconazole in tinea versicolor. Previously, the Company has also shown positive results in Phase 2a trials with pramiconazole in tinea pedis (athlete’s foot), tinea corporis (ring worm), tinea cruris (jock itch), tinea versicolor, vaginal candidiasis and seborrheic dermatitis. The Company is currently seeking to establish a commercial partnership to help fund the further development of this product. About Barrier Therapeutics Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel® (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion® (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at:www.barriertherapeutics.com. Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc. Safe Harbor Statement In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the “Safe Harbor” provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s business development and clinical development plans for pramiconazole and the potential market acceptance of pramiconazole. Forward-looking statements provide Barrier’s current expectations or forecasts of future events. Barrier’s performance and financial results could differ materially from those reflected in these forward-looking statements due to the marketplace acceptance of Barrier’s products, Barrier’s ability to execute its commercial and clinical strategy, the decisions of regulatory authorities, the results of clinical trials and strategic decisions |
